Skip to main content
. 2010 Feb 1;159(6):1236–1246. doi: 10.1111/j.1476-5381.2009.00611.x

Figure 6.

Figure 6

ATB-346 protected the stomach from injury in circumstances in which gastric mucosal defence was impaired. Administration of L-NAME (15 mg·kg−1; A), an inhibitor of nitric oxide synthase, or BCA (50 mg·kg−1; B), an inhibitor of hydrogen sulphide synthesis, significantly increased the severity of gastric damage induced by naproxen (shaded columns; 60 µmol·kg−1; *P < 0.05; Student's t-test), but significant damage was not observed when the rats were treated with an equimolar dose of ATB-346 (solid columns). Pretreatment with glibenclamide (10 mg·kg−1; C), an antagonist of ATP-sensitive potassium (KIR6.x) channels, also significantly increased the severity of naproxen-induced gastric damage, but rats cotreated with ATB-346 did not develop significant gastric injury. Each group consisted of five to six rats. ATB-346, 2-(6-methoxy-napthalen-2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester; BCA, β-cyanoalanine; L-NAME, NG-nitro-L-arginine methylester; Veh, vehicle.